Sanofi and GSK announced on May 27 the start of a phase 3 clinical trial for their COVID-19 recombinant vaccine candidate which, in phase 2 initial results shared May 17, demonstrated strong immune responses across all adult age groups.
Our adjuvanted recombinant protein-based vaccine candidate
The vaccine antigen is the spike protein that will stimulate the immune system to produce antibodies against the virus
Our mRNA-based vaccine candidate
The antigen is produced in the body’s cells using the genetic coding for the spike protein against which the immune system will respond by producing antibodies against the virus
Sanofi’s Commitment to Fighting COVID-19
Throughout the ongoing pandemic, Sanofi has joined forces to fight COVID-19
Frequently Asked Questions (FAQ)
COVID-19 Press Releases
[Pagination JS]
The Impact of COVID-19 on the Prevention and Diagnosis of other Diseases
Vaccines: our best line of defense against infectious diseases like COVID-19
Critical Routine Vaccinations: Getting Back on Track
Preventing the Preventable: Influenza Vaccination in the Time of COVID-19
World Polio Day: Driving Polio Out of Sight, Never Out of Mind
Developing COVID-19 Vaccines: Behind the Scenes
Supporting People with Cancer during COVID-19
